Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Angeion Corporation Reports Record Quarterly Revenues And Profitable Second Quarter Results; 8th Consecutive Quarter Of Double-Digit Year-Over-Year Revenue Growth; 3rd Consecutive Quarter Of Bottom Line Profitability.


SAINT PAUL Saint Paul, city (1990 pop. 272,235), state capital and seat of Ramsey co., E Minn., on bluffs along the Mississippi River, contiguous with Minneapolis, forming the Twin Cities metropolitan area; inc. 1854. , Minn. -- Angeion Corporation (Nasdaq:ANGN) today reported results for its second quarter ended April 30, 2006. Notable second quarter accomplishments included the following:

--Record revenues, totaling $7.2 million

--19.6 percent revenue growth compared to the second quarter of 2005

--Double-digit year-over-year revenue growth for the eighth consecutive quarter

--Net income of $383,000, versus a loss of $238,000 a year ago

--Third consecutive quarter of profitability

Results for the second quarter 2006 compared to the second quarter 2005

Angeion Corporation reported net income of $383,000, or $0.10 per diluted di·lute  
tr.v. di·lut·ed, di·lut·ing, di·lutes
1. To make thinner or less concentrated by adding a liquid such as water.

2. To lessen the force, strength, purity, or brilliance of, especially by admixture.
 share, on total revenues of $7.2 million. This compares with a net loss of $238,000, or $0.07 per diluted share, on total revenues of $6.0 million in the second quarter of 2005. Net income for the second quarter of 2006 included a $272,000 gain from discontinued operations Discontinued operations

Divisions of a business that have been sold or written off and that no longer are maintained by the business.
.

For the six months ended April 30, 2006, total revenue increased 27.9 percent to $14.1 million from $11.1 million for the same period in 2005. Net income for the six months ended April 30, 2006, was $559,000, or $0.15 per diluted share, compared to a net loss of $949,000, or $0.26 per diluted share, for the same period in 2005. Net income for the six months ended April 30, 2006, included a $268,000 gain from discontinued operations.

"We are pleased that our focused sales and marketing initiatives successfully drove our revenue growth and fueled improved profitability in the second quarter," commented Rodney Rodney may refer to:

Surnames
  • Caesar Rodney (1728–1784), Signer of the U.S. Declaration of Independence and President of Delaware
  • Caesar A. Rodney (1772–1824), U.S.
 A. Young, President and Chief Executive Officer. "Our primary emphasis is on gaining market share through new product introductions, creative sales and marketing campaigns, as well as unsurpassed technical support. Our cardiorespiratory car·di·o·res·pi·ra·to·ry  
adj.
Of or relating to the heart and the respiratory system.

Adj. 1. cardiorespiratory - of or pertaining to or affecting both the heart and the lungs and their functions; "cardiopulmonary
 diagnostics (1) Software routines that test hardware components (memory, keyboard, disks, etc.). Diagnostics are often stored in ROM chips and activated on startup.

(2) Error messages in a programmer's source code that refer to statements or syntax that the compiler or assembler
 business for the hospital and physician office markets sustained its momentum resulting in notable growth, particularly in our international markets. The level of consumer participation in New Leaf's Active Metabolic met·a·bol·ic
adj.
Of, relating to, or resulting from metabolism.


Metabolic
Refers to the chemical processes of an organ or organism.
 Training(TM) for the health and fitness club market is significantly outpacing last year's number of client assessments," continued Young.

"In addition, our newest market expansions, the clinical research market that leverages our pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e)
1. pertaining to the lungs.

2. pertaining to the pulmonary artery.


pul·mo·nar·y
adj.
Of, relating to, or affecting the lungs.
 function diagnostic technology to ensure the safety and efficacy efficacy /ef·fi·ca·cy/ (ef´i-kah-se)
1. the ability of an intervention to produce the desired beneficial effect in expert hands and under ideal circumstances.

2.
 of select new pharmaceuticals and devices, along with the weight management and meal planning market, served by our New Leaf EnergySmart(TM) online programs, have already had an important impact on both revenue and our bottom line," according to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 Young.

Looking ahead

"We have made excellent progress on many fronts in the first half of fiscal 2006. We are energized by the growth in revenues and continued profitability. Going forward we will maintain focus on our primary 2006 goals of driving year-over-year growth and sustained profitability. To continue to achieve these goals, we must continue to implement additional creative MedGraphics marketing programs, maintain our focused selling efforts in hospitals and physicians' offices, expand our network of New Leaf health and fitness distribution centers, and increase the number of clinical research studies we support," Young concluded.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics www.medgraphics.com in December December: see month.  1999. Medical Graphics develops, manufactures and markets non-invasive Non-invasive
A procedure that does not penetrate the body.

Mentioned in: Multiple-Gated Acquisition Scan


non-invasive

1. not penetrating the skin, e.g. a non-invasive test.

2.
 diagnostic systems for the management and improvement of cardiorespiratory health. These products are sold internationally through distributors and in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, clinics and physicians' offices. The Company also sells health and fitness products, many of which are derived de·rive  
v. de·rived, de·riv·ing, de·rives

v.tr.
1. To obtain or receive from a source.

2.
 from Medical Graphics' cardiorespiratory product technologies. These products, marketed under the New Leaf health and fitness brand www.newleaffitness.com, help consumers effectively manage their weight and improve their fitness. They are marketed to the consumer primarily through personal training studios, health and fitness clubs and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. These statements by their nature involve substantial risks and uncertainties. Actual results may differ materially depending on a variety of factors, including (i) the Company's ability to successfully operate its Medical Graphics business including its ability to develop, improve, and update its cardiorespiratory diagnostic products, (ii) the Company's ability to successfully sell its New Leaf health and fitness products, (iii) the Company's ability to successfully defend itself from product liability claims related to its Medical Graphics' products and claims associated with its prior cardiac cardiac /car·di·ac/ (-ak)
1. pertaining to the heart.

2. pertaining to the cardia.


car·di·ac
adj.
1. Of, near, or relating to the heart.

2.
 stimulation stimulation /stim·u·la·tion/ (stim?u-la´shun) the act or process of stimulating; the condition of being stimulated.

deep brain stimulation
 products, (iv) the Company's ability to protect its intellectual property, and (v) the Company's dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and any prior discussion is qualified in its entirety The whole, in contradistinction to a moiety or part only. When land is conveyed to Husband and Wife, they do not take by moieties, but both are seised of the entirety.  by, the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October October: see month.  31, 2005, and subsequently filed reports.
Angeion Corporation and Subsidiaries
        Unaudited Condensed Consolidated Financial Statements
                (In thousands, except per share data)

                                  Three Months Ended Six Months Ended
                                      April 30,          April 30,
                                  ------------------ -----------------
                                    2006      2005     2006     2005
                                  --------- -------- -------- --------
Consolidated Statements of
 Operations
---------------------------------
Revenue                             $7,212   $6,032  $14,145  $11,062
Cost of goods sold                   3,647    3,044    7,032    5,741
                                  --------- -------- -------- --------
    Gross margin                     3,565    2,988    7,113    5,321
                                  --------- -------- -------- --------

Operating expenses:
    Selling and marketing            1,774    1,858    3,697    3,565
    General and administrative         942      614    1,715    1,278
    Research and development           549      559    1,021    1,037
    Amortization of intangibles        203      203      406      406
                                  --------- -------- -------- --------
                                     3,468    3,234    6,839    6,286
                                  --------- -------- -------- --------
Operating income (loss)                 97     (246)     274     (965)
    Interest income                     19        8       28       16
                                  --------- -------- -------- --------
Income (loss) before income taxes      116     (238)     302     (949)
    Provision for income taxes           5        -       11        -
                                  --------- -------- -------- --------

Income (loss) from continuing
 operations                            111     (238)     291     (949)
Gain from discontinued operations      272        -      268        -
                                  --------- -------- -------- --------
Net income (loss)                     $383    $(238)    $559    $(949)
                                  ========= ======== ======== ========

Income (loss) per share -basic
    Continuing operations            $0.03   $(0.07)   $0.08   $(0.26)
    Discontinued operations           0.08        -     0.07        -
                                  --------- -------- -------- --------
        Net income (loss)            $0.11   $(0.07)   $0.15   $(0.26)
                                  ========= ======== ======== ========

Income (loss) per share -diluted
    Continuing operations            $0.03   $(0.07)   $0.08   $(0.26)
    Discontinued operations           0.07        -     0.07        -
                                  --------- -------- -------- --------
        Net income (loss)            $0.10   $(0.07)   $0.15   $(0.26)
                                  ========= ======== ======== ========

Weighted average common shares
 outstanding
    Basic                            3,619    3,606    3,615    3,605
    Diluted                          3,760    3,606    3,714    3,605
                                  ========= ======== ======== ========




Consolidated Balance Sheets                     April 30,  October 31,
---------------------------                       2006        2005
                                               ----------- -----------
Cash                                               $2,957      $1,072
Cash restricted for discontinued operations           200         400
Other current assets                               10,869       8,535
Equipment, intangible assets and goodwill           6,525       6,861
                                               ----------- -----------
                                                  $20,551     $16,868
                                               =========== ===========

Current liabilities                                $7,039      $4,279
Long-term liabilities                                 848         656
Shareholders' equity                               12,664      11,933
                                               ----------- -----------
                                                  $20,551     $16,868
                                               =========== ===========
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jun 12, 2006
Words:1133
Previous Article:NIC Lite(R), NICTime's Newly Approved Nicotine Replacement Drink, Hits the Market to Help Cope with Smoking Bans.
Next Article:BSLM Reaches Tentative Agreement to Acquire BRSI.
Topics:



Related Articles
Medical Action Industries reports record revenues for second quarter/six months; Continued improvement in operating results.
Novoste Corporation Reports its First Profitable Quarter.
Zacks Brokerage Buy List: Lockheed Martin, Medtronic, PepsiCo, and Pfizer.
Zacks Brokerage Buy List: Allstate, Apache, Medtronic and Wells Fargo & Company.
Angeion Corporation Reports Record Revenue and Profit in Third Quarter; 4th Consecutive Profitable Quarter & 9th Consecutive Quarter of Double-Digit...
Sensient Technologies Corporation Reports Earnings for the Quarter Ended September 30, 2006.
Zacks' Discount Fundamental Strength Strategy Highlights: Avnet, Inc., ENGlobal Corporation, JLG Industries, Inc. and Triumph Group, Inc.
Angeion Corporation Reports Record Preliminary Fourth Quarter and Fiscal Year Growth in Revenue and Income before Taxes.
Angeion Corporation Reports Record 2006 Fiscal Year and Final Fourth Quarter Results.
Angeion Corporation Reports Strong Revenue and Earnings Growth in First Quarter of 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles